Sofinnova Investments’s ChemoCentryx, Inc. CCXI Stock Holding History

Sofinnova Investments’s Portfolio CCXI Stock Details CCXI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-505,800	Closed	-$8.65M	–	84
2021 Q3	$8.65M	Buy	+505,800	New	+$7.88M	0.51%	41
2021 Q2	–	Sell	-150,000	Closed	-$7.69M	–	78
2021 Q1	$7.69M	Buy	+150,000	New	+$9.02M	0.46%	41

Other funds holding CCXI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

UOC

UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

PCM

Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

SFM

Soros Fund Management New York $9.12B AUM 30.69% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Sofinnova Investments's CCXI Position: Q3 2022 in Review

Sofinnova Investments sold out of ChemoCentryx, Inc. (CCXI) in Q3 2022, closing a stake of 636,659 shares — an estimated $15.8M sold.

Sofinnova Investments first reported a position in CCXI in Q2 2018 and held it in 12 quarters. The position peaked at $26.6M in Q4 2021. 217 funds tracked by Wall St. Rank hold CCXI as of Q3 2022.

Sofinnova Investments reported no remaining ChemoCentryx, Inc. position as of Q3 2022 after selling out during the quarter.
Sofinnova Investments sold 636,659 ChemoCentryx, Inc. shares in Q3 2022, an estimated $15.8M.
Sofinnova Investments first reported a position in ChemoCentryx, Inc. in Q2 2018 and held it in 12 quarters.
Sofinnova Investments's ChemoCentryx, Inc. position peaked at $26.6M in Q4 2021.
217 funds tracked by Wall St. Rank held ChemoCentryx, Inc. as of Q3 2022.

Based on Sofinnova Investments's 13F filing for Q3 2022, filed 8 Nov 2022.